Identification of Novel Low Molecular Weight Serum Peptidome Biomarkers for Non‐Small Cell Lung Cancer (NSCLC)
Juan Yang,Yong-Chun Song,Tu-Sheng Song,Xiao-Yan Hu,You-Min Guo,Zong-Fang Li,Cheng-Xue Dang,Chen Huang
DOI: https://doi.org/10.1002/jcla.21502
IF: 3.124
2012-01-01
Journal of Clinical Laboratory Analysis
Abstract:AimTo identify discriminating protein patterns in serum samples among non‐small cell lung cancer (NSCLC), chronic obstructive pulmonary disease (COPD), pneumonia, and healthy controls. To discover specific low molecular weight (LMW) serum peptidome biomarkers and establish a diagnostic pattern for NSCLCby using proteomic technology.MethodsWe used magnetic bead‐based separation followed by matrix‐assisted laser desorption ionization time‐of‐flight mass spectrometry (MALDI‐TOF MS) to identify patients with NSCLC, COPD, and pneumonia. A total of 154 serum samples were analyzed in this study, among which there were 60 serum samples from NSCLC patients, 30 from patients with other lung‐related diseases (16 pneumonia patients and 14 patients with COPD) as disease controls, and 64 from healthy volunteers as healthy control. The mass spectra, analyzed using ClinProTools software, distinguished between cancer patients and healthy individuals based on GA algorithm model.ResultsIn this study, we generated numerous discriminating m/z peaks as well as disease‐specific discrimination peaks. A set of five potential biomarkers (m/z: 7,763.24, 1,012.61, 4,153.16, 1,450.55, and 2,878.89) could be used as the diagnostic biomarkers to distinguish NSCLCpatients from healthy controls. In the training set, patients with NSCLC could be identified with sensitivity of 97.5% and specificity of 98.8%. Similar results were obtained in the testing set, showing 80.7% sensitivity and 91.2% specificity.ConclusionOur study demonstrated that a combined application of magnetic beads with MALDI‐TOF MS technique was suitable for identification of serum biomarkers for NSCLC. J. Clin. Lab. Anal. 26:148‐154, 2012. © 2012 Wiley Periodicals, Inc.